Research & Literature

Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.

Roehrborn CG, Oyarzabal Perez I, Roos EP, et al.

BJU international 2015; (116(3)):450-9 doi:10.1111/bju.13033.

EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.

Gratzke C, Bachmann A, Descazeaud A, et al.

European urology 2015; (67(6)):1099-1109 doi:10.1016/j.eururo.2014.12.038.

Relationships between Prostatic Volume and Intravesical Prostatic Protrusion on Transabdominal Ultrasound and Benign Prostatic Obstruction in Patients with Lower Urinary Tract Symptoms.

Wang D, Huang H, Law YM, Foo KT

Annals of the Academy of Medicine, Singapore 2015; (44(2)):60-5.

Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study.

Sønksen J, Barber NJ, Speakman MJ, et al.

European urology 2015; (68(4)):643-52.

Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis.

Gong M, Dong W, Huang G, et al.

Current medical research and opinion 2015; (31(9)):1781-92 doi:10.1185/03007995.2015.1074067.

Management of Benign Prostatic Hyperplasia.

Kim EH, Larson JA, Andriole GL

Annual review of medicine 2016; (67()):137-51 doi:10.1146/annurev-med-063014-123902.

Assessment and management of male lower urinary tract symptoms (LUTS).

Abdelmoteleb H, Jefferies ER, Drake MJ

International journal of surgery (London, England) 2016; (25()):164-71.

[Pharmacological treatment of benign prostatic hyperplasia].

Oelke M, Martinelli E

Der Urologe. Ausg. A 2016; (55(1)):81-94; quiz 95-6 doi:10.1007/s00120-015-0011-3.

A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.

Manjunatha R, Pundarikaksha HP, Madhusudhana HR, et al.

Indian journal of pharmacology 2016; (48(2)):134-40 doi:10.4103/0253-7613.178825.

The role of prostate inflammation and fibrosis in lower urinary tract symptoms.

Bushman WA, Jerde TJ

American journal of physiology. Renal physiology 2016; (311(4)):F817-F821 doi:10.1152/ajprenal.00602.2015.

Convective Water Vapor Energy for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia.

DeLay KJ, McVary KT

The Urologic clinics of North America 2016; (43(3)):371-5.

Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia.

Minutoli L, Rinaldi M, Marini H, et al.

International journal of molecular sciences 2016; (17(8)).

Management of Benign Prostatic Hyperplasia in Older Adults.

Woodard TJ, Manigault KR, McBurrows NN, et al.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 2016; (31(8)):412-24 doi:10.4140/TCP.n.2016.412.

Medical and Surgical Treatment Modalities for Lower Urinary Tract Symptoms in the Male Patient Secondary to Benign Prostatic Hyperplasia: A Review.

Macey MR, Raynor MC

Seminars in interventional radiology 2016; (33(3)):217-23 doi:10.1055/s-0036-1586142.

Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study.

Roehrborn CG, Barkin J, Gange SN, et al.

The Canadian journal of urology 2017; (24(3)):8802-8813.

Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia.

Homma Y, Gotoh M, Kawauchi A, et al.

International journal of urology : official journal of the Japanese Urological Association 2017; (24(10)):716-729 doi:10.1111/iju.13401.

Recent research on the role of urodynamic study in the diagnosis and treatment of male lower urinary tract symptoms and urinary incontinence.

Jiang YH, Kuo HC

Tzu chi medical journal 2017; (29(2)):72-78 doi:10.4103/tcmj.tcmj_19_17.

The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis.

Lee SWH, Chan EMC, Lai YK

Scientific reports 2017; (7(1)):7984 doi:10.1038/s41598-017-06628-8.

Holmium Laser Enucleation of the Prostate: Patient Selection and Outcomes.

Kuebker JM, Miller NL

Current urology reports 2017; (18(12)):96 doi:10.1007/s11934-017-0746-z.

Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Jung JH, Kim J, MacDonald R, et al.

The Cochrane database of systematic reviews 2017; (11()):CD012615 doi:10.1002/14651858.CD012615.pub2.

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.

Kim EH, Brockman JA, Andriole GL

Asian journal of urology 2018; (5(1)):28-32 doi:10.1016/j.ajur.2017.11.005.

Urinary Retention in Adults: Evaluation and Initial Management.

Serlin DC, Heidelbaugh JJ, Stoffel JT

American family physician 2018; (98(8)):496-503.

Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.

Gudmundsson J, Sigurdsson JK, Stefansdottir L, et al.

Nature communications 2018; (9(1)):4568 doi:10.1038/s41467-018-06920-9.

Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis.

Karavitakis M, Kyriazis I, Omar MI, et al.

European urology 2019; (75(5)):788-798 doi:10.1016/j.eururo.2019.01.046.

[Diagnostic procedures and diagnostic strategy for lower urinary tract symptoms/benign prostatic hyperplasia : An overview].

Bschleipfer T, Oelke M, Rieken M

Der Urologe. Ausg. A 2019; (58(3)):238-247 doi:10.1007/s00120-019-0870-0.

Benign Prostatic Hyperplasia.

Langan RC

Primary care 2019; (46(2)):223-232 doi:10.1016/j.pop.2019.02.003.

Holmium laser enucleation of the prostate (HoLEP): a review and update.

Das AK, Teplitsky S, Humphreys MR

The Canadian journal of urology 2019; (26(4 Suppl 1)):13-19.

Toll-like receptor 9 regulates metabolic profile and contributes to obesity-induced benign prostatic hyperplasia in mice.

Calmasini FB, McCarthy CG, Wenceslau CF, et al.

Pharmacological reports : PR 2020; (72(1)):179-187 doi:10.1007/s43440-019-00010-3.

Intravesical prostatic protrusion does not compromise the therapeutic effects of Mirabegron in male patients with overactive bladder.

Shen YC, Wang HJ, Lee WC, et al.

International journal of clinical practice 2020; (74(9)):e13537 doi:10.1111/ijcp.13537.

Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2020.

Parsons JK, Dahm P, Köhler TS, et al.

The Journal of urology 2020; (204(4)):799-804 doi:10.1097/JU.0000000000001298.

The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review.

Vickman RE, Franco OE, Moline DC, et al.

Asian journal of urology 2020; (7(3)):191-202 doi:10.1016/j.ajur.2019.10.003.

Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects.

La Vignera S, Aversa A, Cannarella R, et al.

Expert opinion on pharmacotherapy 2021; (22(2)):179-189 doi:10.1080/14656566.2020.1817382.

Mechanistic targets for BPH and prostate cancer-a review.

Shah A, Shah AA, K N, Lobo R

Reviews on environmental health 2021; (36(2)):261-270 doi:10.1515/reveh-2020-0051.

Effectiveness of convective water vapor energy therapy versus prostatic urethral lift for symptomatic benign prostatic hyperplasia: a systematic review and indirect comparison.

Tallman CT, Zantek PF, Hernandez N, et al.

World journal of urology 2021; (39(9)):3207-3215 doi:10.1007/s00345-021-03595-8.

Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART II-Surgical Evaluation and Treatment.

Lerner LB, McVary KT, Barry MJ, et al.

The Journal of urology 2021; (206(4)):818-826 doi:10.1097/JU.0000000000002184.

Prostatic Artery Embolization: Indications, Preparation, Techniques, Imaging Evaluation, Reporting, and Complications.

Dias US, de Moura MRL, Viana PCC, et al.

Radiographics : a review publication of the Radiological Society of North America, Inc 2021; (41(5)):1509-1530 doi:10.1148/rg.2021200144.

[Acute urine retention: Epidemiology, optimization of the care pathway and alternative to permanent bladder drainage].

Baboudjian M, Savoie PH, Long JA, Boissier R

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 2021; (31(15)):967-977 doi:10.1016/j.purol.2021.07.005.

Reliability and validity of assessment methods available in primary care for bladder outlet obstruction and benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review.

Vredeveld T, van Benten E, Beekmans REPM, et al.

BMJ open 2022; (12(4)):e056234 doi:10.1136/bmjopen-2021-056234.

Effect of alpha-adrenoceptor antagonists on sexual function. A systematic review and meta-analysis.

Bapir R, Bhatti KH, Eliwa A, et al.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 2022; (94(2)):252-263 doi:10.4081/aiua.2022.2.252.

Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.

Jin R, Forbes C, Miller NL, et al.

The Prostate 2022; (82(14)):1378-1388 doi:10.1002/pros.24410.

The incidence of urethral stricture and bladder neck contracture with transurethral resection vs. holmium laser enucleation of prostate: A matched, dual-center study.

Elsaqa M, Serag M, Leenlani N, et al.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2023; (17(1)):E35-E38 doi:10.5489/cuaj.7967.

Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing.

Mansbart F, Kienberger G, Sönnichsen A, Mann E

BMC geriatrics 2022; (22(1)):771 doi:10.1186/s12877-022-03415-7.

Urodynamic risk factors of asymptomatic bacteriuria in men with non-neurogenic lower urinary tract symptoms.

Ishida S, Matsukawa Y, Yuba T, et al.

World journal of urology 2022; (40(12)):3035-3041 doi:10.1007/s00345-022-04194-x.

The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.

The lancet. Healthy longevity 2022; (3(11)):e754-e776 doi:10.1016/S2666-7568(22)00213-6.

Relationships between holmium laser enucleation of the prostate and prostate cancer.

Lee MS, Assmus MA, Guo J, et al.

Nature reviews. Urology 2023; (20(4)):226-240 doi:10.1038/s41585-022-00678-y.

Comparative RNA-sequencing analysis of the prostate in a mouse model of benign prostatic hyperplasia with bladder outlet obstruction.

Tang X, Liu Z, Ren J, et al.

Molecular and cellular biochemistry 2023; (478(12)):2721-2737 doi:10.1007/s11010-023-04695-2.

Comparison of the short-term efficacy and safety of bipolar transurethral electro vaporization and holmium laser enucleation of the prostate for moderate and large benign prostatic enlargement.

Hayashi Y, Yoneyama S, Takizawa A, et al.

BMC urology 2023; (23(1)):50 doi:10.1186/s12894-023-01215-8.

How Would You Manage This Patient With Benign Prostatic Hyperplasia? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.

Smetana GW, Smith CC, Singla A, Libman H

Annals of internal medicine 2023; (176(4)):545-555 doi:10.7326/M23-0113.

Management of use of urinary antimuscarinics and alpha blockers for benign prostatic hyperplasia in older adults at risk of falls: a clinical review.

İlhan B, Erdoğan T, Topinková E, et al.

European geriatric medicine 2023; (14(4)):733-746 doi:10.1007/s41999-023-00798-7.

[Diagnostic work-up of benign prostatic hyperplasia : The German S2e-guideline 2023 part 1].

Oelke M, Abt SD, Becher KF, et al.

Urologie (Heidelberg, Germany) 2023; (62(8)):805-817 doi:10.1007/s00120-023-02142-0.

Mechanism of Androgen-Independent Stromal Proliferation in Benign Prostatic Hyperplasia.

Hata J, Harigane Y, Matsuoka K, et al.

International journal of molecular sciences 2023; (24(14)) doi:10.3390/ijms241411634.

Comparison of holmium laser enucleation and transurethral resection of prostate in benign prostatic hyperplasia: a systematic review and meta-analysis.

Chen F, Chen Y, Zou Y, et al.

The Journal of international medical research 2023; (51(8)):3000605231190763 doi:10.1177/03000605231190763.

Prospective Trial of Water Vapor Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia in Subjects with a Large Prostate: 6- and 12-month Outcomes.

Woo H, Levin R, Cantrill C, et al.

European urology open science 2023; (58()):64-72 doi:10.1016/j.euros.2023.10.006.

A Review of Combined Phosphodiesterase-5-Inhibitors and α-Blockers versus Phosphodiesterase-5-Inhibitors Alone for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia.

Jackson EM, Khooblall P, Lundy SD, Bajic P

Arab journal of urology 2024; (22(1)):13-23 doi:10.1080/2090598X.2023.2220627.

Medical Advancements in Benign Prostatic Hyperplasia Treatments.

Ganesan V, Agarwal D

Current urology reports 2024; (25(5)):93-98 doi:10.1007/s11934-024-01199-4.

Summary Paper on Underactive Bladder from the European Association of Urology Guidelines on Non-neurogenic Male Lower Urinary Tract Symptoms.

Baboudjian M, Hashim H, Bhatt N, et al.

European urology 2024; (86(3)):213-220 doi:10.1016/j.eururo.2024.04.004.

Chronic inflammation in benign prostatic hyperplasia: Pathophysiology and treatment options.

Inamura S, Terada N

International journal of urology : official journal of the Japanese Urological Association 2024; (31(9)):968-974 doi:10.1111/iju.15518.

Convective Water Vapor Energy Ablation (Rezum®) Versus Prostatic Urethral Lift (Urolift®): A 2-Year Prospective Study.

Law YXT, Chen WJK, Shen L, et al.

Journal of endourology 2024; (38(12)):1387-1394 doi:10.1089/end.2024.0400.

Association between metabolic syndrome and benign prostatic hyperplasia: The underlying molecular connection.

Fu X, Wang Y, Lu Y, et al.

Life sciences 2024; (358()):123192 doi:10.1016/j.lfs.2024.123192.

Pre-therapeutical assessment of lower urinary tract symptoms in adult men: Systematic review and clinical practice guidelines.

Lebdai S, Doizi S, Kassab D, et al.

The French journal of urology 2025; (35(3)):102846 doi:10.1016/j.fjurol.2024.102846.

Impact of Endoscopic Bladder Outlet Procedures on Medical and Surgical Retreatment: A Large Population Analysis.

Helman T, Patil D, Marthi S, Browne B

Journal of endourology 2025; (39(6)):608-616 doi:10.1089/end.2024.0741.

Reoperation for Benign Prostatic Obstruction Following Transurethral Resection and Holmium Laser Enucleation of the Prostate: A 3-year Follow-up Study of Over 33 000 Primary Surgical Interventions.

Gilfrich C, May M, Gratzke C, et al.

European urology focus 2025; (11(4)):609-617 doi:10.1016/j.euf.2025.02.017.

Lower Urinary Tract Symptoms in Men: A Review.

Wei JT, Dauw CA, Brodsky CN

JAMA 2025; (334(9)):809-821 doi:10.1001/jama.2025.7045.

Non-interventional and medical management of lower urinary tract symptoms related to benign prostatic hyperplasia in men: Guidelines of the French LUTS Committee (CTMH).

Anract J, Klein C, Sarrazin C, et al.

The French journal of urology 2025; (35(11)):102952 doi:10.1016/j.fjurol.2025.102952.

Management of acute urinary retention in men with benign prostatic hyperplasia: Literature review and guidelines from the French Urological Association Male LUTS Panel (CTMH).

Pinar U, Gas J, Sarrazin C, et al.

The French journal of urology 2025; (35(11)):102953 doi:10.1016/j.fjurol.2025.102953.

Real-world comparison of Rezūm® water vapor therapy and transurethral resection of the prostate using a pragmatic composite definition of procedural success.

Pina-Vaz T, Costa Silva A, Henriques M, et al.

World journal of urology 2026; (44(1)).

Summary Paper on the 2026 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms.

Baboudjian M, Creta M, Pyrgidis N, et al.

European urology 2026; (90(1)):44-59 doi:10.1016/j.eururo.2026.03.020.

The Role of the Aging Bladder in Lower Urinary Tract Symptoms: Pathophysiology and Therapeutic Implications in Patients with Benign Prostatic Hyperplasia.

Papanikolaou D, Diamantopoulos C, Sokolakis I, et al.

Medicina (Kaunas, Lithuania) 2026; (62(4)) doi:10.3390/medicina62040685.

Pathophysiological mechanisms of benign prostatic obstruction in men with small prostate volume and the emerging role of ultra-minimally invasive prostatic urethral dilation: a narrative review.

Shen K, Zhang D, Yu L

Frontiers in molecular biosciences 2026; (13()):1886121 doi:10.3389/fmolb.2026.1886121.

Holmium laser enucleation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Sathianathen N, Hwang EC, Brown SJ, et al.

The Cochrane database of systematic reviews 2026; (9()):CD013291 doi:10.1002/14651858.CD013291.pub2.